Ran Nussbaum, Director at Eloxx Pharmaceuticals, Inc. (ELOX), bought 11,851,850 shares at $1.35 ($16.0M) on 2021-05-13, disclosed to the SEC on 2021-05-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.35 | 592,592 | $800K | 5.0% |
| 2 | $1.35 | 592,592 | $800K | 5.0% |
| 3 | $1.35 | 1,280,624 | $1.7M | 10.8% |
| 4 | $1.35 | 1,280,624 | $1.7M | 10.8% |
| 5 | $1.35 | 1,422,222 | $1.9M | 12.0% |
| 6 | $1.35 | 1,422,222 |
| $1.9M |
| 12.0% |
| 7 | $1.35 | 2,630,487 | $3.6M | 22.2% |
| 8 | $1.35 | 2,630,487 | $3.6M | 22.2% |
| Total | $1.35 avg | 11,851,850 | $16.0M | 100% |
| Filing → |
| ARQL | BUY | 2019-07-01 | $4.1M | — | Filing → |
| ELOX | BUY | 2019-06-26 | $1.8M | — | Filing → |
| ARQL | BUY | 2018-10-22 | $1.5M | — | Filing → |